Updates in Antiepileptic Therapy: Evaluating New Agents and Recent Evidence to Aid in the Selection of Treatment

Activity Details
  • Credit Amounts:
    • CME: 1.25
    • CPE: 1.25
    • CNE: 1.25
  • Cost: Free
  • Release: Dec 14, 2016
  • Expires: Dec 14, 2017
  • Estimated Time to Complete:
    1 Hour(s)  15 Minutes
  • System Requirements:
  • Average User Rating:
    (6 Ratings)

Faculty

Randa Jarrar Randa Jarrar, MD
Child Neurologist
Phoenix Children’s Hospital
Clinical Assistant Professor, Department of Pediatrics
University of Arizona
Assistant Professor, Department of Neurology
Mayo Graduate School of Medicine
Phoenix, Arizona

David M.  Spencer David M. Spencer, MD, FAAN
Professor of Neurology
Program Director, Epilepsy and Clinical Neurophysiology Fellowship
Director, Comprehensive Epilepsy Program
Oregon Health and Science University
Portland, Oregon

Needs Statement

Epilepsy is a spectrum of multiple neurologic disorders which are complex in diagnosis, management, and all phases of care.1 An estimated 2.9 million Americans are affected by epilepsy, and 1 in 26 people in the US will develop epilepsy at some point in their lifetime.2,3 The annual direct medical care cost of epilepsy in the US is $15.5 billion, but this figure does not take into account the tremendous amount of indirect costs due to losses in quality of life and productivity, which is the majority of the cost burden of epilepsy.2,4

In the last few years, there have been new additions to the AED armamentarium, offering patients the hope for better control of their epilepsy and the possibility to live healthier and more productive lives. These agents have novel mechanisms of action that may offer better tolerance, favorable pharmacokinetic profiles, fewer interactions, as well as pharmacokinetic and pharmacodynamics advantages.5-7 It is vital for all members of the neurology healthcare team to be aware of these new drugs and how to incorporate them into clinical practice. This educational activity will review the clinical safety and efficacy data of existing and emerging antiepileptics, as well as their place in the therapy of epilepsy. Various factors to aid in the selection of drug therapy for specific patient populations will also be explored in this initiative.

1Chang BS, et al. N Engl J Med. 2003; 2http://www.cdc.gov/epilepsy/basics/fast_facts.htm; 3Hirtz D, et al. Neurology. 2007; 4Yoon D, et al. Epilepsia. 2009; 5Ben-Menachem E, et al. Epilepsia. 2014; 6Verrotti A, et al. Epilepsy Res. 2014; 7Brodie MJ, et al. Neurology. 2012.

Target Audience

This initiative is targeted to neurologists, pediatric neurologists, neuroscience nurses, and pharmacists interested and involved in care of patients with epilepsy.

Objectives

Part 1:

  1. Examine the most recent advances in the treatment of epilepsy with regard to agent mechanism of action, pharmacokinetic profile, drug interactions, and risk of adverse effects.
  2. Appraise clinical safety and efficacy data for new and emerging antiepileptic drugs to elucidate their place in therapy for adult and pediatric epilepsy patients.
  3. Explore how novel drug delivery options and dosage forms for antiepileptic drugs can impact treatment in terms of seizure reduction, tolerability, safety, adherence, ease of administration, and overall patient outcomes.

Part 2:

  1. Examine the most recent advances in the treatment of epilepsy with regard to agent mechanism of action, pharmacokinetic profile, drug interactions, and risk of adverse effects.
  2. Appraise clinical safety and efficacy data for new and emerging antiepileptic drugs to elucidate their place in therapy for adult and pediatric epilepsy patients.

Accreditation

CME

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CEC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement
  • Interpersonal and communication skills
  • Professionalism
  • Systems-based practice

IOM Competencies

  • Provide patient-centered care
  • Work in interdisciplinary teams
  • Employ evidence-based practice
  • Apply quality improvement

IPE Competencies

  • Values/Ethics for Interprofessional Practice
  • Roles/ Responsibilities
  • Interprofessional Communication
  • Teams and Teamwork

CPE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This knowledge-based activity is approved for 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit (UAN 0245-0000-16-006-H01-P).

CNE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is designated for 1.25 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

PLANNERS:

Vanessa Carranza, PharmD, has no relevant financial relationships to disclose in relation to the content of this activity.

AUTHORS/PRESENTERS:

Randa A. Jarrar, MD – has no relevant financial relationships to disclose in relation to the content of this activity.

David Spencer, MD, FAAN – has no relevant financial relationships to disclose in relation to the content of this activity.

Activity Instructions

Media: Internet Web Activity (Powerpoint slides and audio)

Instructions:

To receive a statement of credit, you must:

  • Read the target audience, learning objectives, and author disclosures.
  • Review the full content of the activity and reflect upon its teaching.
  • Complete the questions and evaluation at the end of the activity.
  • You must have a passing score of 70% on the post-test. You will have two (2) opportunities to complete the post-test.